Researchers track drug levels in blood to understand lung cancer treatment response
NCT ID NCT04557007
Summary
This study aims to understand how the amount of pembrolizumab (an immunotherapy drug) in a patient's blood relates to their treatment outcomes for non-small cell lung cancer. Researchers will monitor drug levels and immune cell activity in about 80 patients who are receiving pembrolizumab, either alone or with chemotherapy, as their first treatment. The goal is to gather knowledge that might help predict which patients respond best to this type of therapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
St Olavs University Hospital
Trondheim, Norway
Conditions
Explore the condition pages connected to this study.